SEPSIS AMINOGLYCOSIDES Examples: Streptomycin, Gentamicin

Total Page:16

File Type:pdf, Size:1020Kb

SEPSIS AMINOGLYCOSIDES Examples: Streptomycin, Gentamicin SEPSIS AMINOGLYCOSIDES Examples: streptomycin, gentamicin, tobramycin Mechanism of action A bactericidal group of drugs which inhibit bacterial protein synthesis by irreversibly binding bacterial ribosomes. They require entry to Gram negative bacterial cells through outer cell membrane (via porins) and inner cytoplasmic membrane (an oxygen-dependent system) in order to exert their effect. They have difficulty penetrating Gram positive cell walls. They are therefore effective against Gram negative aerobic bacteria but not against anaerobic gram negative bacteria whose cell wall/membranes the antibiotic cannot penetrate. They have limited application against Gram positive bacteria. Synergistic with penicillins - cell wall synthesis inhibitors increase the permeability of the cell wall to aminoglycosides. They do not cross the blood brain barrier and have low concentrations in many tissues. They reach high concentrations in the inner ears and kidneys. Adverse Effects Ototoxicity - accumulates in the endolymph and perilymph of the inner ear causing deafness, tinnitus and vertigo. Increased risk with co-use of loop diuretics and cisplatin. Nephrotoxicity - retention of aminoglycosides by proximal tubular cells disrupts calcium- mediated transport processes resulting in nephrotoxicity. This ranges from mild, reversible renal impairment to severe, irreversible acute tubular necrosis. Dose, frequency and duration of therapy determine the extent of nephrotoxicity. Other adverse effects - allergy, neuromuscular blockade. They cross the placenta and may cause congenital deafness. Gentamicin Prescribing Where possible prescribe gentamicin using the Gentamicin calculator. If critically ill and gentamicin is needed prescribe 5mg/kg actual body weight (max 400mg). If critically ill and known CKD stage V give 2.5mg/kg (max 180mg). Always prescribe gentamicin on the Gentamicin prescription chart. CAP 14 HAP 14 Stephen Foley 30/09/2016 CAP 14 HAP 14 Stephen Foley 30/09/2016 .
Recommended publications
  • Resistance to Paromomycinis Conferred by Rpsl Mutations
    VOL.53 NO. 12, DEC.2000 THE JOURNAL OF ANTIBIOTICS pp.1424 - 1427 COMMUNICATIONS TO THE EDITOR Resistance to Paromomycinis Conferred by paromomycin at a frequency of 10 7 or 10 8, respectively. rpsL Mutations, Accompaniedby an Out of 77 randomly selected paromomycin resistant Enhanced Antibiotic Production in mutants, 4 strains, designated as KO-347-350, were found to produce actinorhodin in 7 to 10-fold greater amounts Streptomyces coelicolor A3 (2) than the parent strain (Table 1). In our previous studies10'11>14) we established that an antibiotic- Sir: overproducing characteristic frequently appears together Aminoglycoside antibiotics interfere with bacterial with the mutation within the rpsL gene. To address this protein synthesis by binding to the 3OS ribosomal relationship weexamined for the presence of mutations in subunit1>2). Their binding is known to stabilize the tRNA- rpsL. Strikingly, all antibiotic-overproducing mutants mRNAinteraction in the A-site by decreasing the tRNA (Class I) examined had rpsL mutations, resulting in the dissociation rates3). Eventually, aminoglycoside antibiotics alteration of amino acid residue 91 from proline to serine cause a decrease in translational accuracy and inhibit (Table 1). In contrast, another group of paromomycin translocation of the ribosome. Such detrimental effects of resistant mutant, (Class II; KO-351-356) which do not aminoglycoside antibiotics can be circumvented by overproduce antibiotic, was found to have no mutation mutations altering 16S rRNA4~6) or certain ribosomal within the rpsL gene. It should be pointed out that Class I proteins6^; these mutations have been found in either the mutants displayed a higher level of resistance to nucleotide 530 or 915 regions of 16S rRNAor in ribosomal paromomycin than that of Class II mutants (Table 1).
    [Show full text]
  • Inhalation Solution, USP for Oral Inhalation Use What Is Tobramycin
    PATIENT INFORMATION TOBRAMYCIN (TOE-BRA-MYE-SIN) Inhalation Solution, USP for oral inhalation use What is Tobramycin Inhalation Solution? Tobramycin inhalation solution is a prescription medicine that is used to treat people with cystic fibrosis who have a bacterial infection called Pseudomonas aeruginosa. Tobramycin inhalation solution contains an antibacterial medicine called tobramycin (an aminoglycoside). It is not known if tobramycin inhalation solution is safe and effective: in children under 6 years of age in people who have an FEV1 less than 25% or greater than 75% predicted in people who are colonized with a bacterium called Burkholderia cepacia Do not take tobramycin inhalation solution if you are allergic to tobramycin, any of the ingredients in tobramycin inhalation solution, or to any other aminoglycoside antibacterial. See the end of this Patient Information for a complete list of ingredients in tobramycin inhalation solution. Before you take tobramycin inhalation solution, tell your healthcare provider about all of your medical conditions, including if you: have or have had hearing problems (including noises in your ears such as ringing or hissing) have dizziness have or have had kidney problems have or have had problems with muscle weakness such as myasthenia gravis or Parkinson’s disease have or have had breathing problems such as wheezing, coughing, or chest tightness are pregnant or plan to become pregnant. Tobramycin inhalation solution is in a class of drugs that can harm your unborn baby. are breastfeeding or plan to breastfeed. It is not known if tobramycin passes into your breast milk. are receiving aminoglycoside therapy by injection or through a vein (intravenous) while taking tobramycin inhalation solution.
    [Show full text]
  • Guidance for Treatment of Covid-19 in Adults and Children
    GUIDANCE FOR TREATMENT OF COVID-19 IN ADULTS AND CHILDREN Patient population: Adults and pediatric patients with COVID-19 infection, who are admitted on an inpatient floor or to the intensive care unit. Key points: Details regarding isolation/precautions, personal protective equipment, patient movement, family/visitor policy, and cleaning/disinfection can be found here. Clinical symptoms: Range from asymptomatic, uncomplicated upper respiratory tract viral infection to pneumonia, acute respiratory distress syndrome (ARDS), sepsis, and septic shock (Table 1) Diagnosis: See current COVID-19 testing recommendations. Treatment: Based on data from several randomized control trials, Remdesivir may provide a modest benefit in a subgroup of patients hospitalized with COVID-19. See further details regarding patient populations (see below) and Table 2. Table 1. Potential Treatment Recommendations by Severity of Disease for Patients 18 Years or Older Most COVID-19 therapeutics have not been studied in children under 18. The below treatment recommendations may apply to some children, however should be addressed on a case-by-case basis and discussed with Pediatric Infectious Diseases. See specific sections for further details Disease severity Potential Treatment Recommendations (per ID consult discretion based on details in Table 2) Post-exposure prophylaxis • See Post-Exposure Prophylaxis Guidelines No supplemental oxygen • Supportive care • Monoclonal Antibodies may be an option in certain high-risk patients (see eligibility criteria in Table 2) admitted for reasons other than COVID-19 who have mild to moderate symptoms of COVID-19 Low flow supplemental oxygen • Supportive care • Dexamethasone (Exception: Minimal supplemental oxygen (1-2 L) in adults with <7 days of symptoms—uncertain benefit) • Remdesivir High flow supplemental oxygen or non- • Supportive Care invasive mechanical ventilation • Dexamethasone • Tocilizumab (NOTE: currently on shortage and not available for treatment of COVID-19 in patients 18 years an older.
    [Show full text]
  • Farrukh Javaid Malik
    I Farrukh Javaid Malik THESIS PRESENTED TO OBTAIN THE GRADE OF DOCTOR OF THE UNIVERSITY OF BORDEAUX Doctoral School, SP2: Society, Politic, Public Health Specialization Pharmacoepidemiology and Pharmacovigilance By Farrukh Javaid Malik “Analysis of the medicines panorama in Pakistan – The case of antimicrobials: market offer width and consumption.” Under the direction of Prof. Dr. Albert FIGUERAS Defense Date: 28th November 2019 Members of Jury M. Francesco SALVO, Maître de conférences des universités – praticien hospitalier, President Université de Bordeaux M. Albert FIGUERAS, Professeur des universités – praticien hospitalier, Director Université Autonome de Barcelone Mme Antonia AGUSTI, Professeure, Vall dʹHebron University Hospital Referee Mme Montserrat BOSCH, Praticienne hospitalière, Vall dʹHebron University Hospital Referee II Abstract A country’s medicines market is an indicator of its healthcare system, the epidemiological profile, and the prevalent practices therein. It is not only the first logical step to study the characteristics of medicines authorized for marketing, but also a requisite to set up a pharmacovigilance system, thus promoting rational drug utilization. The three medicines market studies presented in the present document were conducted in Pakistan with the aim of describing the characteristics of the pharmaceutical products available in the country as well as their consumption at a national level, with a special focus on antimicrobials. The most important cause of antimicrobial resistance is the inappropriate consumption of antimicrobials. The results of the researches conducted in Pakistan showed some market deficiencies which could be addressed as part of the national antimicrobial stewardship programmes. III Résumé Le marché du médicament d’un pays est un indicateur de son système de santé, de son profil épidémiologique et des pratiques [de prescription] qui y règnent.
    [Show full text]
  • Bacterial Conjunctivitis
    Clinical Ophthalmology Dovepress open access to scientific and medical research Open Access Full Text Article EVIDENCE to PRactICE Bacterial conjunctivitis Cindy Hutnik1 Clinical question: What is the best treatment for bacterial conjunctivitis? Mohammad H Results: Topical antibiotics expedite recovery from bacterial conjunctivitis. The choice of Mohammad-Shahi2 antibiotic usually does not affect outcome. Implementation: Recognition of key distinguishing features of bacterial conjunctivitis 1Ivey Eye Institute, St Joseph Healthcare, London, Ontario; 2Faculty • Pitfalls that can be recognized in the history and physical examination of Medicine, McGill University, • Choice of antibiotic Montreal, Quebec, Canada • When to refer for specialist treatment. Keywords: bacterial conjunctivitis, topical antibiotics Bacterial conjunctivitis Definition: Bacterial conjunctivitis is inflammation of the conjunctiva as a result of bacterial infection. Etiology: Most commonly Staphylococcus species in adults, and Streptococcus pneumonia and the Gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis in children. Contact lens wearers are at particular risk for Gram-negative infections. such as Pseudomonas aeruginosa. Neisseria gonorrhoeae is primarily a neonatal etiology. Incidence: One recent study estimates an annual incidence rate of 135 per 10,000 in the US.1 Economics: The same study found the estimated total direct and indirect cost of treating bacterial conjunctivitis in the US to be $589 million annually. Accounting for a 20% variation in annual inci- dence rate and treatment cost resulted in an estimated cost range of $377 to $857 million per year. Level of evidence used in this summary: Systematic reviews, meta-analyses, and random- ized controlled trials from 1990 to 2010. Search sources: Ovid MEDLINE, PubMed, Cochrane Library, NHS evidence, Clinical Evidence.
    [Show full text]
  • Automated Hilic-MS/MS Method for Therapeutic Drug Monitoring of Aminoglycoside Antibiotics and Vancomycin
    Automated HILiC-MS/MS Method for Therapeutic Drug Monitoring of Aminoglycoside Antibiotics and Vancomycin Mikaël LEVI1, Daisuke KAWAKAMI2, Jun WATANABE1 1 SHIMADZU Corporation, MS Business Unit, Kyoto, Japan; 2 SHIMADZU Corporation, Clinical & Biotechnology Business Unit, Kyoto, Japan Area Ratio Area Ratio y = 0.005292846x² + 0.04278182x - 0.004441359 y = 0.001371438x² + 0.02132510x + 0.00002051234 6.0 4.50 1. Introduction R² = 0.9974212 R = 0.9987098 R² = 0.9990104 R = 0.9995051 4.25 5.5 Curve Fit: Default (Quadratic) Curve Fit: Default (Quadratic) Weighting: 1/C 4.00 Weighting: Default (1/C^2) Zero: Default (Not Forced) Zero: Default (Not Forced) 5.0 3.75 3.50 4.5 Aminoglycoside antibiotics are used for treatment of severe infections, especially in the case of Arbekacin 3.25 Kanamycin 4.0 3.00 2.75 3.5 Gram-negative bacilli infection. However, aminoglycosides have narrow therapeutic indexes due to 2.50 3.0 2.25 2.00 2.5 their nephrotoxicity. Therefore, the benefit of therapeutic drug monitoring (TDM) for aminoglycoside 1.75 2.0 1.50 1.25 1.5 has been well-established. Vancomycin, a glycopeptide antibiotic, often used with aminoglycosides 1.00 1.0 0.75 0.50 0.5 because of their synergism, is also nephrotoxic and need to be monitored as well. 0.25 0.0 0.00 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 0.0 2.5 5.0 7.5 10.0 12.5 15.0 17.5 20.0 22.5 25.0 27.5 30.0 32.5 35.0 37.5 40.0 42.5 45.0 47.5 50.0 Conc.Ratio (mg/L) Conc.Ratio (mg/L) While LC-MS/MS is now considered as the gold standard method for TDM, many clinical laboratories Area Ratio Area Ratio 13 y = 0.0003193042x² + 0.2404682x - 0.001638089 y = 0.00002521235x² + 0.01160575x - 0.0007537159 R² = 0.9995769 R = 0.9997884 0.65 R² = 0.9997885 R = 0.9998942 12 Curve Fit: Default (Quadratic) 0.60 Curve Fit: Quadratic still use immunoassays.
    [Show full text]
  • Streptomycin Sulfate PRODUCT DATA SHEET Issue Date 01/06/2020
    Streptomycin Sulfate PRODUCT DATA SHEET issue date 01/06/2020 Product Name: Streptomycin Sulfate Product Number: S008 CAS Number: 3810-74-0 Molecular Formula: C21H39N7O12 · 1.5H 2SO4 Molecular Weight: 728.69 Form: Powder Appearance: A white or almost white powder Solubility: Acetone: Soluble Chloroform: Soluble Water: >20 mg/mL Source: Streptomyces Griseus pH: 4.5 - 7.0 Storage Conditions: 2­8°C Description: Streptomycin sulfate is a freely soluble aminocyclitol glycoside antibiotic, that was co-discovered by Salman Waksman, Albert Schatz, and Elizabeth Bugie at the Rutgers University in 1943 and was later patented in 1948. Streptomycin is isolated from Streptomyces griseus and shows bacteriostatic activity at low concentrations and bactericidal activity at higher concentrations against mycobacteria and gram-negative bacteria. It is less active against gram-positive bacteria. Streptomycin sulfate has been found to be effective against certain β­lactam sensitive VRE or vancomycin resistant Enterococcus species; a glycopeptide antibiotic resistant "superbug”. Streptomycin sulfate is often used together with penicillin and other agents to inhibit bacterial contamination in cell culture applications. It is recommended for use in molecular biology applications at 25­50μg/mL, in cell culture applications at 100 mg/L and in embryo culture at 50 mg/L. Streptomycin is a protein synthesis inhibitor that acts by binding to the 30S ribosomal subunit at the S12 protein thereby inducing a misreading of the genetic code, inhibiting the initiation of translation of DNA, which then results in death for a susceptible bacterium. Streptomycin has also shown activity as a miRNA inhibitor, that is capable of down-regulating miR-21, a miRNA that is overexpressed in a wide variety of cancers.
    [Show full text]
  • Neomycin—Production and Antibiotic Properties
    NEOMYCIN—PRODUCTION AND ANTIBIOTIC PROPERTIES Selman A. Waksman, … , Hubert A. Lechevalier, Dale A. Harris J Clin Invest. 1949;28(5):934-939. https://doi.org/10.1172/JCI102182. Research Article Find the latest version: https://jci.me/102182/pdf NEOMYCIN-PRODUCTION AND ANTIBIOTIC PROPERTIES 1, 2 3 By SELMAN A. WAKSMAN, HUBERT A. LECHEVALIER, AND DALE A. HARRIS (From the Department of Microbiology, New Jersey Agricultural Experiment Station, Rutgers University, New Brunswick, N. J.) ANTIBIOTIC SURVEYS All these cultures proved to be highly active against mycobacteria. of During the last 10 years, a large number anti- Only few of the cultures, however, that gave biotics which are active against Gram-negative good activity by the agar-streak method yielded and Gram-positive bacteria, mycobacteria, rickett- filtrates which possessed corresponding potency. siae, and certain of the larger viruses were iso- This may be due to a variety of factors, such as lated (1) from various species and strains of the the formation by a single organism of more than genus Streptomyces. This served to focus atten- one antibiotic or the production of different anti- tion on the actinomycetes as potential producers of biotics under different conditions of culture. One antimicrobial agents that might possess promising of these cultures proved to be highly promising chemotherapeutic properties. The fact that nearly and was selected for more detailed investigations. 20 to 50%o of these organisms possess antimicrobial This culture was entered into the Collection as No. activities served to heighten this interest. Numer- 3535. The nature of its antimicrobial spectrum, ous surveys have been conducted.
    [Show full text]
  • (ESVAC) Web-Based Sales and Animal Population
    16 July 2019 EMA/210691/2015-Rev.2 Veterinary Medicines Division European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) Sales Data and Animal Population Data Collection Protocol (version 3) Superseded by a new version Superseded Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. Table of content 1. Introduction ....................................................................................................................... 3 1.1. Terms of reference ........................................................................................................... 3 1.2. Approach ........................................................................................................................ 3 1.3. Target groups of the protocol and templates ......................................................................... 4 1.4. Organization of the ESVAC project ...................................................................................... 4 1.5. Web based delivery of data ................................................................................................ 5 2. ESVAC sales data ............................................................................................................... 5 2.1.
    [Show full text]
  • Empirical Antimicrobial Therapy for Children with Cystic Fibrosis
    Empirical antimicrobial therapy for children with Cystic Fibrosis Document ID CHQ-GDL-01073 Version no. 2.0 Approval date 17/12/2020 Executive sponsor Executive Director of Medical Services Effective date 17/12/2020 Director Respiratory Medicine Review date 17/12/2022 Author/custodian Director Infection Management and Prevention Service, Immunology and Rheumatology Supersedes 1.1 Applicable to All Children’s Health Queensland staff Authorisation Executive Director Clinical Services (QCH) Purpose This guideline provides Children’s Health Queensland (CHQ) recommendations for empirical antimicrobial therapy for children with Cystic Fibrosis (CF), for inpatient and outpatient management. Scope This guideline provides information for CHQ staff caring for paediatric CF patients. Related documents Procedures, Guidelines, Protocols • CHQ Paediatric Therapeutic Drug Monitoring – Tobramycin/Gentamicin • CHQ Paediatric Therapeutic Drug Monitoring - Vancomycin • CHQ@Home Outpatient Parenteral Antimicrobial Therapy Prescribing, Administration and monitoring guideline • CHQ-PROC-01036 Antimicrobial: Prescribing, Management and Stewardship and CHQ Antimicrobial Restriction list • CHQ-PROC-63223 Management of patients with cystic fibrosis • CHQ-GDL-01061 Immunisation Guideline for Medically at Risk Children • CHQ-GDL-01076 Paediatric antibiotic allergy assessment, testing and de-labelling • CHQ-GDL-70047 Clinical guidelines for the care of children and adolescents with Cystic Fibrosis - Volume 1: Respiratory Care Guideline Empirical antimicrobial therapy
    [Show full text]
  • Fisher Bioreagents Antibiotics and Antimycotics Catalog
    Fisher BioReagents® Antibiotics and Antimycotics In many life science laboratories, the in vitro culturing of bacterial, Optimized for cell culture plant, and animal cells is a routine task. High quality antibiotics and antimycotics from Fisher BioReagents can be used to ensure success- ful growth of cells by eliminating unwanted bacterial strains and fungi while maintaining the health and vitality of the desired cells. Advantages • High quality - antibiotics and antimycotics meet rigorous quality control tests, including verifi cation of potency, purity, and solubility using microbiological and chromatographic methods. • Built for selection - excellent choice of antibiotics for selection of antibiotic resistance genes in both bacterial and mammalian cells. • High purity and stability - ultrapure antibiotics ensure successful growth of target cells and reproducible results. • Maximum convenience - antibiotics and antimycotics come in both sterile powder and liquid forms. Applications • Plant cell culture • Mammalian cell culture • Tissue culture • Genetic marker selection Table 1. Antibiotic modes of action Molecular Catalog No. Product Description Mode of Action Susceptible Organisms Form Size Packaging Weight Inhibitor of protein disulfide isomerase. Interferes with BP2950-1 Bacitracin 1422.7 Gram+ Dry 1g Amber glass bottle building blocks of peptidoglycan bacterial cell wall. Inhibitor of bacterial cell wall synthesis. Eliminates BP2951-1 Cefotaxime Sodium Salt 477.5 Gram- Dry 1g Amber glass bottle Agrobacterium species after inoculation. BP2952- Prokaryotes and higher Crimp top on glass Hygromycin B 527.5 Inhibits protein synthesis. Liquid 1mu 1MU eukaryotes bottle Alters membrane permeability and allows potassium ion BP2949-5 Nystatin 926.1 Yeasts and molds Dry 5g Amber glass bottle leakage. BP2953-1 Paromomycin Sulfate 615.6 Inhibits protein synthesis.
    [Show full text]
  • Third ESVAC Report
    Sales of veterinary antimicrobial agents in 25 EU/EEA countries in 2011 Third ESVAC report An agency of the European Union The mission of the European Medicines Agency is to foster scientific excellence in the evaluation and supervision of medicines, for the benefit of public and animal health. Legal role Guiding principles The European Medicines Agency is the European Union • We are strongly committed to public and animal (EU) body responsible for coordinating the existing health. scientific resources put at its disposal by Member States • We make independent recommendations based on for the evaluation, supervision and pharmacovigilance scientific evidence, using state-of-the-art knowledge of medicinal products. and expertise in our field. • We support research and innovation to stimulate the The Agency provides the Member States and the development of better medicines. institutions of the EU the best-possible scientific advice on any question relating to the evaluation of the quality, • We value the contribution of our partners and stake- safety and efficacy of medicinal products for human or holders to our work. veterinary use referred to it in accordance with the • We assure continual improvement of our processes provisions of EU legislation relating to medicinal prod- and procedures, in accordance with recognised quality ucts. standards. • We adhere to high standards of professional and Principal activities personal integrity. Working with the Member States and the European • We communicate in an open, transparent manner Commission as partners in a European medicines with all of our partners, stakeholders and colleagues. network, the European Medicines Agency: • We promote the well-being, motivation and ongoing professional development of every member of the • provides independent, science-based recommenda- Agency.
    [Show full text]